Bl-arc002

Phase 1

SSichuan Baili Pharmaceutical Co., Ltd.

Bl-arc002 is one of 49 therapeutic programs targeting Gastrointestinal Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Gastrointestinal TumorsNot yet recruiting

Solid TumorRecruiting

Gastrointestinal TumorsPhase 1

Not yet recruiting

Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Nubeqa

Bayer

Preclinical

2 2

Fludara

Sanofi

Preclinical

1 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 6

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 9

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 10

Tulmimetostat

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Solid Tumor

NCT07591155

Q4 2028

Phase 1Not yet recruiting

Gastrointestinal Tumors

NCT07763652

Clinical

Trials by Indication[1]

Gastrointestinal Tumors1 trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-ARC002 Injection in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT07763652·22 enrolled

Solid Tumor1 trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of BL-ARC002 for Injection in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT07591155·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Bl-arc002. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bl-arc002. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

Bl-arc002

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Gastrointestinal Tumors1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News